Activity Overview
This online, on-demand virtual symposium brings together experts in neurotrophic keratitis (NK). In this educational program, these experts discuss how to identify NK in practice, highlighting indications for corneal sensitivity testing based on patient history and examination findings. Faculty will discuss how to perform corneal sensitivity testing and then how to stage and treat NK once diagnosed.
This educational activity is an archive of the virtual symposium
held on May 2, 2026.
Target Audience
This educational activity is directed toward ophthalmologists, optometrists, and other eye care professionals involved in the management of patients with neurotrophic keratitis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the signs and symptoms that contribute to a diagnosis of neurotrophic keratitis, including reduced or absent corneal sensitivity
- Integrate the Mackie classification system to stage neurotrophic keratitis as part of the comprehensive clinical evaluation
- Summarize recommendations for corneal sensitivity testing based on patient history and clinical findings
- Implement corneal sensitivity testing to evaluate patients with suspected ocular surface disease
Francis Mah, MD
Director, Cornea Service
Co-Director, Refractive Surgery Service
Scripps Clinic Torrey Pines
La Jolla, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Alcon, Aperta, Azura, Bausch + Lomb, BioTissue, BVI, ClearSight, Evolve, Eyenovia, EyeYon, Glaukos, Invirsa, iView, Johnson & Johnson Vision, Kala Bio, Lenz, OcuTerra, OSRX, PMN, PolyActiva, Puget Sound Therapeutics, Signal12, Sophia Bio, STAAR, Sydnexis, Tarsus, Viatris, Yuyu Pharma, Zeiss; Ownership Interests in Privately Held Companies: Avellino Group, Eyenovia, Horizon Surgical Systems, iView, Kala Bio, Okogen, OSRX, Puget Sound Therapeutics, Signal12, Sophia Bio, Sydnexis
Amy Nau, OD, FAAO, Dipl. CCLRT
Adjunct Associate Professor
New England College of Optometry
Co-Owner, Forefront Eye Care
Co-Founder/CEO, Eyewell
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: InMode; Speakers Bureau: Tarsus, Vital Tears; Equity Owner: Eyewell, Forefront Eye Care; Other: Educational Sponsorship: BioTissue, Dompé, Glaukos, InMode, Lacrifill, Lumenis, Ocubio, RxSight
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information
presented and apply their own clinical judgment when considering patient care
decisions.